Leap Therapeutics Inc (LPTX) — Cash Flow-to-Debt Ratio
Leap Therapeutics Inc (LPTX) has a Cash Flow-to-Debt Ratio of -1.87x as of September 2025, meaning its operating cash flow of $-16.29 Million could theoretically repay -2% of its total liabilities ($8.70 Million) in one year. See LPTX free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Leap Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Leap Therapeutics Inc across 13 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Leap Therapeutics Inc.
Annual Cash Flow-to-Debt Ratio for Leap Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Leap Therapeutics Inc. Check how high is Leap Therapeutics Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -4.28x | $-60.30 Million | $14.08 Million | ▼ -24.2% |
| 2023 | -3.45x | $-43.75 Million | $12.68 Million | ▲ +75.7% |
| 2022 | -14.22x | $-49.04 Million | $3.45 Million | ▼ -305.4% |
| 2021 | -3.51x | $-35.16 Million | $10.02 Million | ▲ +59.3% |
| 2020 | -8.62x | $-25.96 Million | $3.01 Million | ▼ -194.8% |
| 2019 | -2.93x | $-26.90 Million | $9.20 Million | ▼ -11.2% |
| 2018 | -2.63x | $-26.03 Million | $9.90 Million | ▼ -113.2% |
| 2017 | -1.23x | $-22.14 Million | $17.95 Million | ▲ +68.6% |
| 2016 | -3.92x | $-25.34 Million | $6.46 Million | ▲ +74.4% |
| 2015 | -15.31x | $-19.58 Million | $1.28 Million | ▼ -111.4% |
| 2014 | -7.24x | $-18.02 Million | $2.49 Million | ▼ -43.6% |
| 2013 | -5.04x | $-9.94 Million | $1.97 Million | ▼ -208.1% |
| 2012 | -1.64x | $-7.55 Million | $4.61 Million | — |